Nintedanib (BIBF 1120) plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma—an international, multicenter, randomized, double-blind, placebo-controlled phase II study
ASCO_2014_-_Meso_Poster.pdf
(779.59 KB, 下载次数: 55)
|